[Cytoreductive surgery and hyperthermic intrathoracic chemotherapy perfusion].
Recently cytoreductive surgery of primary and secondary pleural tumors has been combined with hyperthermic intrathoracic chemotherapy perfusion (HITHOC) for better local tumor control. In comparison to simple instillation of chemotherapeutic agents into the pleural cavity, the combination of surgical resection of pleural tumors and simultaneous HITHOC seems to be a more effective treatment. Intra-operative perfusion allows an improved distribution of the drug in the pleural space and a higher local concentration of the chemotherapeutic agents in contrast to systemic chemotherapy. Additional advantages of HITHOC are a better response to chemotherapeutic agents and synergistic antineoplastic effects. A prerequisite for safe application of HITHOC is compliance with safety regulations. Due to the reduction in morbidity and mortality this new concept is a valuable alternative for selected patients who do not undergo radical resection (e.g. extrapleural pneumonectomy). HITHOC is an additional therapeutic option in the multimodal treatment of patients with primary or secondary tumors of the pleura.
Hofmann
H-S
HS
Abteilung für Thoraxchirurgie, Universitätsklinikum Regensburg, Franz-Josef-Strauss-Allee 11, Regensburg, Germany. hans-stefan.hofmann@klinik.uni-regensburg.de
Wiebe
K
K
D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D017024:Chemotherapy, Adjuvant; D010478:Chemotherapy, Cancer, Regional Perfusion / Q000379:methods*; D003131:Combined Modality Therapy; D006801:Humans; D006979:Hyperthermia, Induced / Q000295:instrumentation*; D008654:Mesothelioma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D009367:Neoplasm Staging; D010994:Pleura / Q000473:pathology / Q000601:surgery; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000556:secondary / Q000601:surgery*; D013945:Thymoma / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D013953:Thymus Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*
D000970:Antineoplastic Agents
J Clin Oncol. 2006 Apr 1;24(10):1561-7
16575008
Eur J Cardiothorac Surg. 2008 Oct;34(4):886-91
18656373
J Surg Oncol. 2001 Nov;78(3):171-4
11745800
J Clin Oncol. 1992 Jun;10(6):1001-6
1588364
Br J Cancer. 1995 Nov;72(5):1283-8
7577483
Ann Surg. 1999 Oct;230(4):562-72; discussion 572-4
10522726
Chest. 2004 Oct;126(4):1318-29
15486399
Eur J Cancer. 1991;27(7):839-42
1834113
J Thorac Cardiovasc Surg. 1999 Jan;117(1):54-63; discussion 63-5
9869758
J Appl Physiol (1985). 1986 Jun;60(6):1980-5
3722063
J Thorac Cardiovasc Surg. 2009 Aug;138(2):405-11
19619785
Ann Surg Oncol. 2003 Mar;10(2):176-82
12620914
J Clin Oncol. 1999 Jul;17(7):2280-9
10561285
Cancer. 1983 Dec 1;52(11):1981-5
6627213
Am J Clin Oncol. 1994 Feb;17(1):80-2
8311014
J Thorac Cardiovasc Surg. 1997 Jan;113(1):55-63
9011702
Chest Surg Clin N Am. 1994 Feb;4(1):113-26
8055276
Chest. 2002 Feb;121(2):480-7
11834661
Ann Thorac Surg. 2001 Aug;72(2):366-70
11515868
J Clin Oncol. 2003 Jul 15;21(14):2636-44
12860938
J Clin Oncol. 2005 Oct 1;23(28):6881-9
16192580
World J Surg Oncol. 2009 Jan 08;7:5
19133112
Lung Cancer. 2001 Feb-Mar;31(2-3):303-10
11165411
Cancer. 1978 Oct;42(4):1692-6
709531
Med J Aust. 1991 Apr 1;154(7):455-7, 460
1706465
Cancer. 2001 Oct 15;92(8):2197-203
11596038
Ann Thorac Surg. 1997 Feb;63(2):334-8
9033296
J Thorac Cardiovasc Surg. 2009 Feb;137(2):453-8
19185169
J Thorac Cardiovasc Surg. 1999 Apr;117(4):759-65
10096972
Pneumonologie. 1972;148(1):60-5
4640028